What is a stock summary page? Click here for an overview.
Business Description
RenovoRx Inc
NAICS : 541714
SIC : 2834
ISIN : US75989R1077
Description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.71 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -42.6 | |||||
| 3-Year EPS without NRI Growth Rate | -36.7 | |||||
| 3-Year FCF Growth Rate | -33.3 | |||||
| 3-Year Book Growth Rate | 45.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 49.45 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.46 | |||||
| 9-Day RSI | 52.14 | |||||
| 14-Day RSI | 48.71 | |||||
| 3-1 Month Momentum % | -23.08 | |||||
| 6-1 Month Momentum % | -5.67 | |||||
| 12-1 Month Momentum % | -27.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.66 | |||||
| Quick Ratio | 5.66 | |||||
| Cash Ratio | 5.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 | |||||
| Shareholder Yield % | -41.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -303.09 | |||||
| ROA % | -144.04 | |||||
| ROIC % | -3524.39 | |||||
| 3-Year ROIIC % | 228.13 | |||||
| ROCE % | -203.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.46 | |||||
| Price-to-Tangible-Book | 3.4 | |||||
| EV-to-EBIT | -2.64 | |||||
| EV-to-EBITDA | -2.64 | |||||
| EV-to-Forward-EBITDA | -3.45 | |||||
| EV-to-Forward-Revenue | 53.43 | |||||
| EV-to-FCF | -3.05 | |||||
| Price-to-Net-Current-Asset-Value | 3.52 | |||||
| Price-to-Net-Cash | 3.64 | |||||
| Earnings Yield (Greenblatt) % | -37.88 | |||||
| FCF Yield % | -24.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNXT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RenovoRx Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.57 | ||
| Beta | 1.18 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 49.56 | ||
| 14-Day RSI | 48.71 | ||
| 14-Day ATR ($) | 0.082221 | ||
| 20-Day SMA ($) | 0.98051 | ||
| 12-1 Month Momentum % | -27.54 | ||
| 52-Week Range ($) | 0.7736 - 1.6899 | ||
| Shares Outstanding (Mil) | 35.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RenovoRx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RenovoRx Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
RenovoRx Inc Frequently Asked Questions
What is RenovoRx Inc(RNXT)'s stock price today?
The current price of RNXT is $1.02. The 52 week high of RNXT is $1.69 and 52 week low is $0.77.
When is next earnings date of RenovoRx Inc(RNXT)?
The next earnings date of RenovoRx Inc(RNXT) is 2025-05-09 Est..
Does RenovoRx Inc(RNXT) pay dividends? If so, how much?
RenovoRx Inc(RNXT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers